1. Home
  2. NNVC vs ELOX Comparison

NNVC vs ELOX Comparison

Compare NNVC & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NNVC

NanoViricides Inc.

HOLD

Current Price

$1.42

Market Cap

37.9M

Sector

Health Care

ML Signal

HOLD

Logo Eloxx Pharmaceuticals Inc. Common Stock

ELOX

Eloxx Pharmaceuticals Inc. Common Stock

N/A

Current Price

$17.62

Market Cap

41.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NNVC
ELOX
Founded
2005
N/A
Country
United States
United States
Employees
N/A
7
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.9M
41.0M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
NNVC
ELOX
Price
$1.42
$17.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
359.1K
55.5K
Earning Date
05-15-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
10.00
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.85
$10.00
52 Week High
$2.23
$19.36

Technical Indicators

Market Signals
Indicator
NNVC
ELOX
Relative Strength Index (RSI) 40.90 67.66
Support Level $1.13 $10.74
Resistance Level $1.47 $19.36
Average True Range (ATR) 0.12 2.00
MACD -0.03 0.72
Stochastic Oscillator 7.37 80.34

Price Performance

Historical Comparison
NNVC
ELOX

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

About ELOX Eloxx Pharmaceuticals Inc. Common Stock

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.

Share on Social Networks: